Canagliflozin
From Proteopedia
(Difference between revisions)
| Line 2: | Line 2: | ||
Canagliflozin, sold under the brand name Invokana among others, is a medication used to treat type 2 diabetes. It is used together with exercise and diet. It is not recommended in type 1 diabetes.<ref name="a2">[https://www.drugs.com/monograph/canagliflozin.html "Canagliflozin Monograph for Professionals".] Drugs.com. American Society of Health-System Pharmacists. Retrieved 6 April 2019.</ref> See also [https://en.wikipedia.org/wiki/Canagliflozin Canagliflozin]. | Canagliflozin, sold under the brand name Invokana among others, is a medication used to treat type 2 diabetes. It is used together with exercise and diet. It is not recommended in type 1 diabetes.<ref name="a2">[https://www.drugs.com/monograph/canagliflozin.html "Canagliflozin Monograph for Professionals".] Drugs.com. American Society of Health-System Pharmacists. Retrieved 6 April 2019.</ref> See also [https://en.wikipedia.org/wiki/Canagliflozin Canagliflozin]. | ||
| - | Canagliflozin is an inhibitor of subtype 2 | + | Canagliflozin is an inhibitor of subtype 2 [[Sodium/glucose cotransporter]] (SGLT2), which is responsible for at least 90% of renal glucose reabsorption (the remaining 10% is done by SGLT1). Blocking this transporter causes up to 119 grams of blood glucose per day to be eliminated through the urine,<ref name="a34">[https://clarivate.com/products/biopharma/ "Integrity - Clarivate"]</ref> corresponding to 476 kilocalories. Additional water is eliminated by osmotic diuresis, resulting in a lowering of blood pressure. |
Canagliflozin also inhibits renal SGLT1, contributing to about 10% of daily urinary glucose excretion.<ref name="a35">PMID:32064793</ref><ref name="a36">PMID:34232488</ref> | Canagliflozin also inhibits renal SGLT1, contributing to about 10% of daily urinary glucose excretion.<ref name="a35">PMID:32064793</ref><ref name="a36">PMID:34232488</ref> | ||
Current revision
| |||||||||||
References
- ↑ "Canagliflozin Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 6 April 2019.
- ↑ "Integrity - Clarivate"
- ↑ Sokolov V, Yakovleva T, Chu L, Tang W, Greasley PJ, Johansson S, Peskov K, Helmlinger G, Boulton DW, Penland RC. Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling. CPT Pharmacometrics Syst Pharmacol. 2020 Apr;9(4):222-229. PMID:32064793 doi:10.1002/psp4.12498
- ↑ Koufakis T, Mustafa OG, Tsimihodimos V, Ajjan RA, Kotsa K. Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection? Drugs. 2021 Aug;81(12):1365-1371. PMID:34232488 doi:10.1007/s40265-021-01559-1
- ↑ Klement A (20 January 2014). "Tubuläre Senkung des Blutzuckers bei Diabetes mellitus: Invokana". Österreichische Apothekerzeitung (in German) (2/2014): 20f.
